Protein SUMOylation confers sorafenib resistance in human hepatocellular carcinoma via the induction of PKM2-mediated glycolysis
{{output}}
Sorafenib resistance remains a major challenge in the treatment of hepatocellular carcinoma (HCC). Through an in vivo CRISPR/Cas9 screen, we identified protein SUMOylation as a key pathway enriched in sorafenib-resistant HCC tumors. SUMO1 expression was signif... ...
